|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPLP1 |
Gene summary for RPLP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPLP1 | Gene ID | 6176 |
| Gene name | ribosomal protein lateral stalk subunit P1 | |
| Gene Alias | LP1 | |
| Cytomap | 15q23 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | A0A024R608 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6176 | RPLP1 | CA_HPV_2 | Human | Cervix | CC | 7.41e-13 | -1.77e-01 | 0.0391 |
| 6176 | RPLP1 | CA_HPV_3 | Human | Cervix | CC | 5.39e-04 | 7.76e-02 | 0.0414 |
| 6176 | RPLP1 | CCI_1 | Human | Cervix | CC | 2.51e-72 | -2.11e+00 | 0.528 |
| 6176 | RPLP1 | CCI_2 | Human | Cervix | CC | 6.31e-34 | -1.30e+00 | 0.5249 |
| 6176 | RPLP1 | CCI_3 | Human | Cervix | CC | 4.75e-105 | -2.24e+00 | 0.516 |
| 6176 | RPLP1 | CCII_1 | Human | Cervix | CC | 7.88e-107 | -2.37e+00 | 0.3249 |
| 6176 | RPLP1 | Tumor | Human | Cervix | CC | 3.13e-17 | -1.27e-01 | 0.1241 |
| 6176 | RPLP1 | sample1 | Human | Cervix | CC | 1.32e-10 | -1.83e-01 | 0.0959 |
| 6176 | RPLP1 | sample3 | Human | Cervix | CC | 3.05e-35 | -2.05e-01 | 0.1387 |
| 6176 | RPLP1 | H2 | Human | Cervix | HSIL_HPV | 2.18e-64 | -4.01e-01 | 0.0632 |
| 6176 | RPLP1 | T1 | Human | Cervix | CC | 3.50e-36 | -2.73e-01 | 0.0918 |
| 6176 | RPLP1 | T3 | Human | Cervix | CC | 1.76e-39 | -2.05e-01 | 0.1389 |
| 6176 | RPLP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.34e-103 | 2.47e+00 | 0.0155 |
| 6176 | RPLP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.58e-61 | 3.27e+00 | -0.1808 |
| 6176 | RPLP1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.59e-38 | 3.52e+00 | 0.0216 |
| 6176 | RPLP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.98e-61 | 3.15e+00 | -0.0811 |
| 6176 | RPLP1 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.59e-47 | 1.71e+00 | -0.1088 |
| 6176 | RPLP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.75e-95 | 3.39e+00 | -0.1954 |
| 6176 | RPLP1 | HTA11_411_2000001011 | Human | Colorectum | SER | 8.01e-26 | 3.42e+00 | -0.2602 |
| 6176 | RPLP1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.76e-19 | 3.28e+00 | -0.2196 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
| GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:003367413 | Cervix | HSIL_HPV | positive regulation of kinase activity | 34/737 | 467/18723 | 4.49e-04 | 6.63e-03 | 34 |
| GO:004586013 | Cervix | HSIL_HPV | positive regulation of protein kinase activity | 27/737 | 386/18723 | 2.93e-03 | 2.74e-02 | 27 |
| GO:00064148 | Cervix | HSIL_HPV | translational elongation | 7/737 | 55/18723 | 5.59e-03 | 4.47e-02 | 7 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
| GO:0045860 | Colorectum | AD | positive regulation of protein kinase activity | 107/3918 | 386/18723 | 8.01e-04 | 7.92e-03 | 107 |
| GO:0006414 | Colorectum | AD | translational elongation | 21/3918 | 55/18723 | 2.53e-03 | 1.93e-02 | 21 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00336741 | Colorectum | SER | positive regulation of kinase activity | 95/2897 | 467/18723 | 2.62e-03 | 2.41e-02 | 95 |
| GO:00064141 | Colorectum | SER | translational elongation | 17/2897 | 55/18723 | 3.00e-03 | 2.65e-02 | 17 |
| GO:00458601 | Colorectum | SER | positive regulation of protein kinase activity | 79/2897 | 386/18723 | 4.85e-03 | 3.79e-02 | 79 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:00336742 | Colorectum | MSS | positive regulation of kinase activity | 122/3467 | 467/18723 | 2.50e-05 | 5.21e-04 | 122 |
| GO:00458602 | Colorectum | MSS | positive regulation of protein kinase activity | 102/3467 | 386/18723 | 6.93e-05 | 1.20e-03 | 102 |
| GO:00064142 | Colorectum | MSS | translational elongation | 19/3467 | 55/18723 | 3.47e-03 | 2.59e-02 | 19 |
| GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPLP1 | deletion | Frame_Shift_Del | c.339delT | p.Phe113LeufsTer7 | p.F113Lfs*7 | P05386 | protein_coding | TCGA-CK-5912-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| RPLP1 | SNV | Missense_Mutation | novel | c.64N>T | p.Thr22Ser | p.T22S | P05386 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| RPLP1 | SNV | Missense_Mutation | novel | c.200G>T | p.Gly67Val | p.G67V | P05386 | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RPLP1 | SNV | Missense_Mutation | rs766033183 | c.149N>T | p.Ala50Val | p.A50V | P05386 | protein_coding | tolerated(0.06) | possibly_damaging(0.764) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| RPLP1 | SNV | Missense_Mutation | c.299N>G | p.Glu100Gly | p.E100G | P05386 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |